i had to sell for tax purposes but that was a hell of a good run from almost 21 not long ago it cant hurt to take some profits.
for the BCBS coverage like they did on AETNA
when do you think we will hear about that?
Exact Sciences ($EXAS) kicked off 2015 with big plans for reimbursement for its stool-based DNA colon cancer test, and now the company has scored key coverage decisions from two major insurers for its diagnostic tool.
The Madison, WI-based company nabbed coverage from Aetna ($AET) and Anthem ($ANTM) for its Cologuard test, a critical win as Exact looks to chart growth for the tool in the coming year. As of April 1, Aetna's Medicare Advantage plan will cover the noninvasive diagnostic without a copayment or co-insurance, making Cologuard available to 967,000 members.
Anthem will cover the test as a medically necessary procedure once every three years "as a screening technique for individuals in whom colon cancer preventive screening is indicated," the insurer said in a policy statement, broadening Cologuard's reach. Anthem covers more than 68 million people including 37 million lives in its health plans.
A cautious revenue projection for the company three to five years from now I believe is $1.5 billion per year. That does not include any increase in compliance for testing despite the goal of the American Cancer Society being 80% and the tests short-term experience being about 75%.
The plan has 967,000 members across the country, and the three year agreement will go into effect on April 1, 2015.
The test will be available to Aetna's Medicare Advantage members through their physician without a co-payment or co-insurance.
Lake Street Capital initiated coverage on shares of EXACT Sciences They set a “buy” rating and a $33.00 price target on the stock